Table 4.
Univariate and multivariate Cox analysis of PFS for patients receiving the CapTem regimen from baseline (CapTem initiation).
| Variable | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| HR (95% CI) | p Value | HR (95% CI) | p Value | |
| Gender | 0.904 | |||
| Female | 1 | |||
| Male | 0.879 (0.109–7.084) | |||
| Age | 0.593 | |||
| <50 | 1 | |||
| ⩾50 | 1.408 (0.401–4.942) | |||
| Inheritance | 0.337 | |||
| Sporadic | 1 | |||
| Familial (MEN1) | 2.773 (0.345–22.270) | |||
| Functional status | 0.668 | |||
| Nonfunctioning | 1 | |||
| Functioning | 0.639 (0.083–4.930) | |||
| TNM | 0.469 | |||
| III | 1 | |||
| IV | 23.190 (0.005–114483.176) | |||
| Ki67 index | 0.601 | |||
| ⩽10% | 1 | |||
| >10% | 0.737 (0.235–2.312) | |||
| Mitosis | 0.199 | |||
| ⩽10 | 1 | |||
| >10 | 2.439 (0.626–9.498) | |||
| MGMT expression | 0.758 | |||
| Negative to moderate | 1 | |||
| High | 1.207 (0.365–3.996) | |||
| FDG-SUVmax (tumor/liver) | 0.139 | |||
| ⩽2 | 1 | |||
| >2 | 0.416 (0.130–1.331) | |||
| SSA-SUVmax (tumor/liver) | 0.894 | |||
| ⩽1 | 1 | |||
| >1 | 0.914 (0.246–3.393) | |||
| Prior surgery | 0.052 | 0.732 | ||
| No | 1 | 1 | ||
| Yes | 3.225 (0.990–10.509) | 1.299 (0.291–5.799) | ||
| CapTem line of treatment | 0.148 | |||
| First line (naïve) | 1 | |||
| ⩾Second line (pretreated) | 2.591 (0.712–9.424) | |||
| Lymph node metastasis | 0.602 | |||
| No | 1 | |||
| Yes | 0.708 (0.193–2.594) | |||
| Pleura metastasis | 0.858 | |||
| No | 1 | |||
| Yes | 1.105 (0.369–3.308) | |||
| Pericardium metastasis | 0.281 | |||
| No | 1 | |||
| Yes | 2.090 (0.548–7.976) | |||
| Lung metastasis | 0.678 | |||
| No | 1 | |||
| Yes | 1.315 (0.361–4.785) | |||
| Pancreas metastasis | 0.483 | |||
| No | 1 | |||
| Yes | 0.481 (0.062–3.727) | |||
| Liver metastasis | 0.626 | |||
| No | 1 | |||
| Yes | 0.044 (0–12175.405) | |||
| Bone metastasis | 0.074 | 0.964 | ||
| No | 1 | 1 | ||
| Yes | 6.431 (0.833–49.664) | 190985.623 (0–9.473E + 232) | ||
| Blood parameters | ||||
| NLR | 0.960 (0.811–1.136) | 0.636 | ||
| LMR | 1.320 (0.988–1.764) | 0.06 | 1.285 (0.632–2.613) | 0.489 |
| PLR | 2.676 (1.509–4.745) | 0.001** | 3.707 (1.086–12.654) | 0.036* |
| AFP | 9.213 (0–547076.711) | 0.692 | ||
| CEA | 1.829 (0.463–7.215) | 0.389 | ||
| CA125 | 0.977 (0.841–1.135) | 0.761 | ||
| SCC | 0.727 (0.023–22.535) | 0.856 | ||
| CA199 | 0.937 (0.661–1.327) | 0.714 | ||
| PIVKA-II | 0.063 (0.000–10.598) | 0.290 | ||
| NSE | 1.081 (0.881–1.326) | 0.456 | ||
| CFRA21-1 | 1.695 (0.913–3.147) | 0.095 | 1.018 (0.306–3.387) | 0.977 |
| ProGRP | 1.005 (0.965–1.047) | 0.805 | ||
| LDH | 0.480 (0.086–2.689) | 0.404 | ||
AFP, alpha-fetoprotein; CA125, carbohydrate antigen 125; CA199, carbohydrate antigen 199; CapTem, capecitabine and temozolomide; CEA, carcinoembryonic antigen; CFRA21-1, cytokeratin 19 fragment; FDG-SUVmax, fluorodeoxyglucose standardized uptake value maximum; LDH, lactate dehydrogenase; LMR, lymphocyte-to-monocyte ratio; MGMT, O6-methylguanine DNA methyltransferase; NLR, neutrophil-to-lymphocyte ratio; NSE, protein induced by vitamin K absence or antagonist II; PFS, progression-free survival; PIVKA-II, protein induced by vitamin K absence or antagonist II; PLR, platelet-to-lymphocyte ratio; ProGRP, pro-gastrin-releasing peptide; SCC, squamous cell carcinoma antigen; SSA-SUVmax, somatostatin analogues standardized uptake value maximum; TNM, tumor-node-metastasis.
The bold values indicate significant values.